Week in Review: Sinocare Acquires Second US Diagnostics Maker; Pays $200 Million

Shangsha's Sinocare will pay up to $200 million to acquire PTS Diagnostics of Indianapolis, a blood testing device maker; Founder Securities of China joined forces with Korea Investment Partners for a $300 million Asia healthcare fund; CSPC Pharma of Shijiazhuang out-licensed global rights (ex-China) for a generic oncology drug to Watson Laboratories; Ideaya Biosciences, a San Francisco-San Diego oncology startup, closed a $46 million Series A funding with WuXi Healthcare Ventures participating; Sirnaomics, a Maryland developer of RNAi therapeutics, raised $10 million in a Series B financing, led by Hong Kong's Value Measured Investment Limited; Jiangsu Hengrui Medicine signed a three-year oncology research agreement with MD Anderson Cancer Center; Innovative Cellular Therapeutics, a China cell therapy company, said its CAR-T product achieved a 90% remission rate in leukemia patients with a poor prognosis; and China Jo-Jo Drugstores, a pharmacy chain in Zhejiang province, received CFDA approval giving virtual doctors permission to write prescriptions in clinics at six of its retail locations. More details.... Stock Symbols: (SHZ: 300298) (HK: 01093) (SHA: 600276) (NSDQ CM: CJJD) Share this with colleagues: // //